What's happened
On April 2, 2026, President Trump signed executive orders imposing up to 100% tariffs on foreign-made patented pharmaceuticals that do not meet pricing or US manufacturing conditions. Companies with pricing deals and US production face zero tariffs; others face escalating tariffs over four years. The orders also revise tariffs on steel, aluminum, and copper products to be based on full US market value.
What's behind the headline?
Strategic Use of Tariffs to Reshape Pharma and Metals Industries
President Trump's new tariffs represent a calculated escalation in his trade policy, leveraging import duties to force pharmaceutical companies to lower prices and increase US manufacturing. The zero-percent tariff exemption for companies that sign 'most favored nation' pricing deals and build US facilities creates a clear incentive structure favoring large, established firms like Pfizer and Eli Lilly, who have already signed such deals.
Impact on Smaller Drugmakers and Market Dynamics
Smaller and mid-sized drugmakers face a steep tariff climb—from 20% to 100% over four years—unless they negotiate deals or onshore production. This creates a two-tiered system that could disadvantage emerging companies lacking diversified portfolios, potentially reducing competition and innovation in the US pharmaceutical market.
National Security Framing and Political Timing
Framing tariffs as necessary to protect national security underscores the administration's broader narrative linking economic policy to geopolitical strength. The timing on the first anniversary of 'Liberation Day' tariffs signals a recommitment to aggressive trade measures despite recent legal setbacks.
Metals Tariff Recalculation and Industry Effects
Adjusting tariffs on steel, aluminum, and copper to be based on full US market value rather than foreign production costs closes loopholes that importers exploited. This will raise costs for products with significant metal content, affecting industries reliant on imported components and finished goods.
Forecast and Consequences
The tariffs will likely accelerate pharmaceutical onshoring but raise drug costs in the short term due to increased production expenses and tariffs on imports. The metals tariff changes will protect domestic producers but increase costs for manufacturers using imported metal components. Politically, these moves reinforce Trump's trade agenda but risk backlash from smaller drugmakers and industries dependent on imported metals.
What the papers say
The New York Times' Ana Swanson highlights the administration's dual focus on pharmaceuticals and metals, noting the simplification of tariffs on products with significant metal content: "Any product where steel, aluminum or copper makes up more than 15 percent by weight will pay a flat 25 percent tariff on the entire value of the product." The Guardian's Lauren Aratani emphasizes the creation of a "two-tiered system of exemptions," warning that mid-sized drugmakers "lack diversified portfolios to absorb these sudden cost increases." She also notes the exemption of generic drugs and specialty medicines, which make up the majority of US prescriptions.
Al Jazeera and France 24 provide detailed accounts of the tariff structure, with Al Jazeera quoting a senior administration official who said companies have months to negotiate before 100% tariffs apply, and noting 17 pricing deals with major drugmakers, 13 signed. The NY Post's Steven Nelson underscores the tariff relief for large companies that have pledged 'most favored nations' pricing and US production, while smaller firms face escalating tariffs.
Politico frames the tariffs as part of a broader trade strategy, marking the anniversary of the original 'Liberation Day' tariffs and highlighting the administration's efforts to cap tariffs for countries with trade agreements. The coverage collectively illustrates a complex policy balancing protectionism, negotiation leverage, and industry incentives.
How we got here
Since the start of his second term, Trump has pursued aggressive import tariffs to protect US industries and lower drug prices. Last year’s 'Liberation Day' tariffs were overturned by the Supreme Court in February 2026. The new orders target pharmaceutical imports and metals, aiming to boost domestic production and address national security concerns.
Go deeper
- How will these tariffs affect drug prices for consumers?
- What incentives do pharmaceutical companies have to build US manufacturing facilities?
- How will the new metals tariff calculations impact US manufacturers?
Common question
-
How Are US Steel Tariffs Changing in 2026?
Steel tariffs are a hot topic in 2026, with significant changes in US policies impacting global markets. The US has introduced a simplified tariff system, imposing a flat 25% rate on certain imported metals, aiming to protect domestic industries. Meanwhile, the UK faces unique challenges with loopholes that could undermine tariff efforts. Curious about how these changes affect manufacturing, prices, and international trade? Keep reading to find out what you need to know about the evolving steel tariffs this year.
-
How Are US and UK Tariffs on Metals Changing?
Recent developments in US and UK trade policies are reshaping the global steel and metal markets. The US has introduced a simplified 25% flat tariff on certain imported metals, while the UK faces challenges with loopholes that could undermine its steel industry. These changes raise questions about their impact on jobs, global trade, and industry protection. Below, we explore the key questions and what they mean for the future of metal trade.
More on these topics
-
Donald John Trump is an American politician, media personality, and businessman who served as the 45th president of the United States from 2017 to 2021.
-
A tariff is a tax imposed by a government of a country or of a supranational union on imports or exports of goods. Besides being a source of revenue for the government, import duties can also be a form of regulation of foreign trade and policy that taxes
-
The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients, with the aim to cure them, vaccinate them, or alleviate the symptoms.